MeiraGTx Holdings plc (MGTX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
MeiraGTx Holdings plc (MGTX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
MGTX - MeiraGTx Holdings plc
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$23.33
DETAILS
HIGH:
$26.00
LOW:
$20.00
MEDIAN:
$24.00
CONSENSUS:
$23.33
UPSIDE:
152.49%
Stock News
MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
LONDON and NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced that the Compensation Committee of the Company's Board of Directors approved equity awards to Penny Fleck in connection with her employment with the Company as Chief Development Officer. The equity awards were granted as an inducement material to the new employee entering employment with MeiraGTx in accordance with Nasdaq Listing Rule 5635(c)(4).
MeiraGTx Holdings PLC (MGTX) Reports Q1 Loss, Lags Revenue Estimates
MeiraGTx Holdings PLC (MGTX) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to a loss of $0.51 per share a year ago.
MeiraGTx Reports First Quarter 2026 Financial and Operational Results
Received FDA Breakthrough Therapy Designation for AAV2-hAQP1 Reported positive three-year data from the Phase 1 AQUAx study of AAV2-hAQP1 for the treatment of grade 2/3 late radiation-induced xerostomia Entered into an asset purchase agreement with Johnson & Johnson* (J&J) to acquire all interests in botaretigene sparoparvovec (bota-vec) for the treatment of X-linked retinitis pigmentosa (XLRP) Strengthened balance sheet with $100 million financing LONDON and NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced financial and operational results for the first quarter ended March 31, 2026, and provided a corporate update. “Our achievements in the first few months of 2026 have materially strengthened MeiraGTx – we are now in a position to file for potential approval and launch two wholly-owned therapies in the next 2 years,” said Alexandria Forbes, Ph.D.
Will MeiraGTx Holdings PLC (MGTX) Report Negative Q1 Earnings? What You Should Know
MeiraGTx (MGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MeiraGTx (MGTX) Soars 6.8%: Is Further Upside Left in the Stock?
MeiraGTx (MGTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
MeiraGTx (NASDAQ:MGTX) Sees Strong Trading Volume on Analyst Upgrade
MeiraGTx Holdings PLC (NASDAQ: MGTX - Get Free Report) shares saw unusually-strong trading volume on Friday after Royal Bank Of Canada raised their price target on the stock from $16.00 to $24.00. Royal Bank Of Canada currently has an outperform rating on the stock. Approximately 623,122 shares traded hands during trading, an increase of 13% from
MeiraGTx Holdings plc (MGTX) Discusses 3-Year Phase I Data on AAV-hAQP1 for Radiation-Induced Xerostomia and Commercial Opportunity Transcript
MeiraGTx Holdings plc (MGTX) Discusses 3-Year Phase I Data on AAV-hAQP1 for Radiation-Induced Xerostomia and Commercial Opportunity Transcript
Eli Lilly Partner MeiraGTx Regains Rights For Genetic Eye Disease Drug From Johnson & Johnson
XLRP is a severe, progressive genetic eye disease causing early-onset night blindness and peripheral vision loss, leading to legal blindness by age 40–45.
MeiraGTx Announces Pricing of $100 Million Offering of Ordinary Shares
LONDON and NEW YORK, April 16, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced the pricing of an underwritten offering of 11,111,111 of its ordinary shares at an offering price of $9.00 per share. Gross proceeds to MeiraGTx from the offering are expected to be approximately $100 million, before deducting underwriting discounts and commissions and offering expenses. All of the ordinary shares in the offering are being sold by MeiraGTx.
MeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec (bota-vec) for the Treatment of X-linked Retinitis Pigmentosa (XLRP)
LONDON and NEW YORK, April 16, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced that it has entered into an asset purchase agreement with Johnson & Johnson* (J&J) to acquire all interests in bota-vec for the treatment of XLRP.
MeiraGTx Announces Positive Three-year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Late Radiation-Induced Xerostomia
LONDON and NEW YORK, April 16, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced positive three-year data from the completed Phase 1 AQUAx study of AAV-hAQP1 for the treatment of grade 2/3 late radiation-induced xerostomia (RIX).
MeiraGTx: Turning Dry Mouth Into Liquid Gold
MeiraGTx is approaching a pivotal Phase 1 data readout for AAV-hAQP1 in radiation-induced xerostomia, with the stock recently hitting 52-week highs. MGTX's riboswitch-controlled gene therapy platform, vertical integration, and big pharma partnerships differentiate its approach and support an ambitious pipeline. I estimate AAV2hAQP1's peak sales at ~$1.2B, with risk-adjusted NPV of $979.8M, and see tomorrow's data as a major de-risking event.
MeiraGTx to Present 3-Year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Thursday, April 16, 2026
- Presentation to include 3-year data from all cohorts of the Phase 1 AQUAx Clinical Study - Cohort-level data and individual patient data from bilateral and unilateral cohorts will be presented for both PRO and objective measures. LONDON and NEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced it will host a conference call and webcast to present 3-year data from the long-term follow-up of patients in the Phase 1 study of AAV-hAQP1 for the treatment of persistent grade 2/3 moderate to severe radiation-induced xerostomia (RIX) on Thursday, April 16, 2026, at 8:00 a.m.
Strength Seen in MeiraGTx (MGTX): Can Its 6.2% Jump Turn into More Strength?
MeiraGTx (MGTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
MeiraGTx Holdings plc (MGTX) Presents at RBC Capital Markets Virtual Ophthalmology Conference Transcript
MeiraGTx Holdings plc (MGTX) Presents at RBC Capital Markets Virtual Ophthalmology Conference Transcript
Alexandria Forbes Sells 62,000 Shares of MeiraGTx (NASDAQ:MGTX) Stock
MeiraGTx Holdings PLC (NASDAQ: MGTX - Get Free Report) CEO Alexandria Forbes sold 62,000 shares of the stock in a transaction that occurred on Tuesday, March 24th. The shares were sold at an average price of $7.41, for a total transaction of $459,420.00. Following the completion of the sale, the chief executive officer owned 1,449,695 shares
MeiraGTx Holdings PLC (MGTX) Q4 Earnings and Revenues Surpass Estimates
MeiraGTx Holdings PLC (MGTX) came out with quarterly earnings of $0.19 per share, beating the Zacks Consensus Estimate of a loss of $0.6 per share. This compares to a loss of $0.5 per share a year ago.
MeiraGTx Announces FDA Breakthrough Therapy Designation for AAV2-hAQP1 for the Treatment of Grade 2 and Grade 3 Radiation-Induced Xerostomia (RIX) and Reports Fourth Quarter and Full Year 2025 Financial and Operational Results
FDA granted Breakthrough Therapy Designation for AAV2-hAQP1 for the treatment of Grade 2 and Grade 3 late xerostomia caused by radiotherapy for cancers of the upper aerodigestive tract MeiraGTx to hold a program update and present long-term data for AAV2-hAQP1 program for the treatment of Grade 2/3 Radiation-Induced Xerostomia on Thursday, April 16 th , 2026 LONDON and NEW YORK, March 26, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced financial and operational results for the fourth quarter and full-year ended December 31, 2025, and provided a corporate update. “We are delighted to have been awarded Breakthrough Designation for our AAV2-hAQP1 treatment for Grade 2 and Grade 3 late xerostomia caused by radiotherapy for cancers of the upper aerodigestive tract,” said Alexandria Forbes, Ph.D.
MeiraGTx Holdings PLC (NASDAQ:MGTX) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Shares of MeiraGTx Holdings PLC (NASDAQ: MGTX - Get Free Report) have received an average rating of "Moderate Buy" from the seven ratings firms that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, four have issued a buy rating
Price Targets
MeiraGTx price target raised to $24 from $16 at RBC Capital
$24.00
(was $10.11)
RBC Capital
MeiraGTx price target lowered to $26 from $30 at Piper Sandler
$26.00
(was $7.62)
Piper Sandler
MeiraGTx initiated with a Buy at H.C. Wainwright
$20.00
(was $7.46)
Mitchell Kapoor
·
H.C. Wainwright
MeiraGTx Holdings plc (MGTX) PT Raised at RBC Capital Amid LLY Deal
$16.00
(was $8.35)
Lisa Walter
·
RBC Capital
MeiraGTx price target lowered to $9 from $11 at RBC Capital
$9.00
(was $4.02)
Luca Issi
·
RBC Capital